Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion
This study has been terminated.
Study NCT00969293
Information provided by Fovea Pharmaceuticals SA
First Received on August 31, 2009.
Last Updated on January 9, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
